Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares Ultra Bloomberg Natural Gas ETF (BOIL) vs Revvity Inc (RVTY) Price & Performance

ProShares Ultra Bloomberg Natural Gas ETFTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

ProShares Ultra Bloomberg Natural Gas ETF vs Revvity Inc — how do they compare? ProShares Ultra Bloomberg Natural Gas ETF trades at $21.87, while Revvity Inc trades at $110.91 (market cap $12.41B). The key difference: Revvity Inc pays a 0.25% dividend while ProShares Ultra Bloomberg Natural Gas ETF pays none, and Revvity Inc is trading nearer its 52-week high, ProShares Ultra Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.

BOILRVTY
Sector
Leveraged / InverseTechnology
52-Week High
$98.62$117.75
52-Week Low
$21.86$82.26
Market Cap
$12.41B
Enterprise Value
$14.90B
Dividend Yield
0.25%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares Ultra Bloomberg Natural Gas ETF

BOIL trades at $21.86, down 3.62% on the day, with technical indicators showing a bearish trend despite oversold RSI readings. The stock recently underwent a 1:2 split on May 28, 2026. Natural gas market volatility dominates sentiment, with futures fluctuating based on weather forecasts and LNG demand. Fundamental data remains unavailable, highlighting the speculative nature of this leveraged ETF.

The outlook remains highly speculative given BOIL's leveraged structure and dependence on natural gas price movements. Key risks include contango erosion and weather-driven volatility. Investment opportunity exists for tactical traders betting on natural gas price surges, but long-term value erosion remains a significant concern for buy-and-hold investors.

Revvity Inc

RVTY trades at $111.11, down 1.05% today, with a bullish technical signal from moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $1.06 exceeding expectations. Recent developments include AI integration with Anthropic's Claude and FDA clearance for a testosterone assay, signaling innovation in diagnostics and life sciences.

The outlook remains positive with strong analyst support (51.72% buy ratings) and a consensus price target of $111.43. Key risks include margin pressure from China divestment plans and weak academic demand. Revenue stability around $2.9B supports valuation, though high P/E of 53.47 requires sustained growth to justify.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ProShares Ultra Bloomberg Natural Gas ETF

BOIL is a leveraged ETF that seeks to provide two times (2x) the daily performance of the Bloomberg Natural Gas Subindex. It uses futures contracts to offer magnified exposure to natural gas price movements.

Read more on BOIL

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY